{"id":968549,"date":"2026-05-29T07:33:17","date_gmt":"2026-05-29T11:33:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/"},"modified":"2026-05-29T07:33:17","modified_gmt":"2026-05-29T11:33:17","slug":"at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/","title":{"rendered":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research"},"content":{"rendered":"<h2>\nOver 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SEATTLE, May  29, 2026  (GLOBE NEWSWIRE) &#8212; Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ<sup>\u00ae<\/sup> test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm.<\/p>\n<p>Data at ASCO and EHA this year continue to reinforce clonoSEQ\u2019s role in modern hematologic oncology care \u2014 as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Across hematologic malignancies, these studies highlight how MRD measured by clonoSEQ continues to be broadly incorporated into both research and clinical practice:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Multiple myeloma: Highly sensitive MRD testing continues to demonstrate depth and durability of response across novel therapies, including follow-up data from the inMMyCAR trial of CAR T-cell therapy and bispecific antibody data from MONUMENTAL-3. In addition, a final analysis from the CEPHEUS trial, the basis for the first-ever FDA approval based on an MRD endpoint, showed higher rates of sustained MRD negativity in patients treated with quadruplet regimen daratumumab plus VRd (bortezomib, lenalidomide, and dexamethasone).<\/li>\n<li style=\"margin-bottom:8pt\">Chronic lymphocytic leukemia (CLL): MRD is being incorporated into decisions around therapy duration and discontinuation in studies including BOVen-\u2206MRD400 and venetoSTOP, the latter demonstrating that personalized venetoclax treatment duration based on uMRD5 status leads to durable treatment-free remissions.<\/li>\n<li style=\"margin-bottom:8pt\">Acute lymphoblastic leukemia (ALL): In a Phase 2 study evaluating dose-adjusted EPOCH with rituximab and tafasitamab, MRD assessment with clonoSEQ continues to outperform flow cytometry in detecting residual disease and predicting patient outcomes and can be used to assess disease burden in cerebrospinal fluid.<\/li>\n<li style=\"margin-bottom:8pt\">Lymphoma: clonoSEQ leverages sensitivity and specificity to support MRD testing in real-world and clinical trial settings across multiple major lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).<\/li>\n<\/ul>\n<p>At EHA this year, new data further expand the evidence base for highly sensitive, next-generation sequencing\u2013based MRD assessment and underscore the increasingly global nature of clonoSEQ\u2019s reach and impact. Across Europe, growing momentum behind MRD-guided care is being driven, in part, by increasing biopharmaceutical industry investment in interventional studies that incorporate MRD into treatment decisions.<\/p>\n<p>\u201cThe range of data presentations leveraging clonoSEQ testing at ASCO and EHA this year reflects the maturation of the hematologic MRD field, with key studies highlighting how MRD can define deep responses to new therapies or regimens, including as a primary endpoint, and guide adaptive treatment approaches based on MRD status,&#8221; said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. \u201cAs MRD testing becomes standard practice in hematologic malignancies, the need for clonoSEQ\u2014the only technology specifically designed for the unique biology of blood cancers and capable of delivering highly sensitive and specific MRD assessment throughout the patient treatment journey\u2014has never been greater.\u201d<\/p>\n<p>The full list of abstracts can be viewed <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JbDQmApW2nXD70goOf68nejIO07w5VSyA7XYci4OKvwoVxCABzL8-EZPngOu3XdPvAc8HO2eVn1QrBKQBRBH3ZI5hN23u2TYamIYE9cYVL1eXr3DYNa0JqKikjHGzi-v5AFSq7JoxbZ6K7w0SWKRPjw87MSdW7j89Rt9mscMYeS5EHoTVwpcn4BHvzfPF3rk\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>About clonoSEQ <\/strong><br \/>\n        <br \/>clonoSEQ<sup>\u00ae<\/sup> is the first and only FDA-cleared in vitro diagnostic (IVD)\u00a0test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.<\/p>\n<p>clonoSEQ identifies and quantifies DNA sequences in malignant cells\u2014detecting one cancer cell in one million healthy cells\u2014to help clinicians and researchers\u00a0assess and\u00a0monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.<\/p>\n<p>clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.<\/p>\n<p>To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com\/technical-summary.<\/p>\n<p>\n        <strong>About Adaptive Biotechnologies<\/strong><br \/>\n        <br \/>Adaptive Biotechnologies (\u201cwe\u201d or \u201cour\u201d) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature\u2019s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n<p>In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in the documents we file with the\u00a0Securities and Exchange Commission\u00a0from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n<p>\n        <strong>ADAPTIVE INVESTORS<\/strong><br \/>\n        <br \/>Karina Calzadilla, Vice President, Investor Relations and FP&amp;A<br \/>201-396-1687<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EeY2dYNt6swMeuxzaORgLosoB5qzZNW93EUucQdDyZKjqxNN8xIfgPVSxKht-lar7z6kxqiRCXiQTet1qK9oUdzbz_4FeBIm4RW1XUiYJFSvBZhVRi5G-F6b8mjQlXlR\" rel=\"nofollow\" target=\"_blank\">investors@adaptivebiotech.com<\/a><\/p>\n<p>\n        <strong>ADAPTIVE MEDIA<br \/><\/strong>Erica Jones, Associate Corporate Communications Director<br \/>206-279-2423<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8-nNoGrHuCgmM0rd5L_ZBuE47wZIBnO0podTVbMNfS9jftaOvr3B6Ek6PB1mPLp4qdNX_WmQ2WnSqDjenShYX9ifteKRlAtVdTXh4J6Clwm6D4TBOSBKbALNLbkDxykT\" rel=\"nofollow\" target=\"_blank\">media@adaptivebiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQ4Njk2ZDUtOTQ4Mi00ZDlhLWE4NWItMTUxYTRmODlhNDczLTExODg3NTItMjAyNi0wNS0yOS1lbg==\/tiny\/Adaptive-Biotechnologies.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ\u00ae test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968549","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ\u00ae test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA &hellip; Continue reading &quot;At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T11:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research\",\"datePublished\":\"2026-05-29T11:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/\"},\"wordCount\":1185,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/\",\"name\":\"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\",\"datePublished\":\"2026-05-29T11:33:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/","og_locale":"en_US","og_type":"article","og_title":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk","og_description":"Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ\u00ae test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO and EHA &hellip; Continue reading \"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-29T11:33:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research","datePublished":"2026-05-29T11:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/"},"wordCount":1185,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/","name":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=","datePublished":"2026-05-29T11:33:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODY5NiM3NjI3MjUzIzIxNzcxODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseq-mrd-testing-across-hematology-clinical-practice-and-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ\u00ae MRD Testing Across Hematology Clinical Practice and Research"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968549"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968549\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}